Alex Haahr Gouliaev
CEO, Nuevolution A/S
I received my Ph.D. in Medicinal Chemistry from Aarhus University, Denmark in 1996. My Ph.D. thesis addressed the synthesis of memory enhancing compounds as well as their biological mechanism of action.
In 1996, I joined Neurosearch A/S as a medicinal chemist and was later appointed Director of Chemistry. At Neurosearch my research focused on the discovery of small molecule drug candidates for CNS diseases as well as synthetic route optimization. During this, I was involved in the research for compounds acting on monoamine reuptake, glutamatergic receptors and ion-channels.
In 2001, I co-founded Nuevolution A/S. At Nuevolution, I have been involved in the development of novel methods for synthesis and screening of multi-million member DNA-tagged small molecule libraries
Billion member DNA-tagged screening libraries. From theory to practical application in medicinal chemistry
Since 2001, Nuevolution has researched methods for producing and screening of multi-million member DNA-tagged small molecule libraries for lead discovery, wherein the DNA encode the synthetic history and chemical structure. During the presentation, we will discuss the lesions and scientific solutions discovered during ten years of development and application of this technique.